SOCIOECONOMIC DISPARITIES IN USE OF CARDIOPROTECTIVE MEDICATIONS AMONG PATIENTS WITH PERIPHERAL ARTERIAL DISEASE_AN ANALYSIS OF THE AMERICAN COLLEGE OF CARDIOLOGY&apos;S NCDR PINNACLE REGISTRY  by Subherwal, Sumeet et al.
Quality of Care and Outcomes Assessment
E1838
JACC March 27, 2012
Volume 59, Issue 13
SOCIOECONOMIC DISPARITIES IN USE OF CARDIOPROTECTIVE MEDICATIONS AMONG PATIENTS WITH 
PERIPHERAL ARTERIAL DISEASE_AN ANALYSIS OF THE AMERICAN COLLEGE OF CARDIOLOGY’S NCDR 
PINNACLE REGISTRY
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 9:30 a.m.-10:30 a.m.
Session Title: Cost Effective Care
Abstract Category: 31. Quality of Care and Outcomes Assessment
Presentation Number: 1256-288
Authors: Sumeet Subherwal, Manesh Patel, Fengming Tang, Kim Smolderen, William S. Jones, Henry Ting, Thomas Tsai, John Spertus, Paul Chan, 
Duke University, Durham, NC, USA, Mid American Heart Institute, Kansas City, MO, USA
Background: Peripheral artery disease (PAD) disproportionately affects those of lower socioeconomic status (SES) and is associated with elevated 
cardiovascular risk. The intensity of secondary prevention with cardioprotective medications has rarely been documented, particularly as a function 
of patients’ SES.
Methods: Within the NCDR PINNACLE Registry, 55,126 patients with PAD were categorized into quintiles of SES, defined by family income. The 
association between SES and guidelines-based treatment with anti-platelet and statin medications was evaluated using sequential hierarchical 
models, initially adjusted for practice site and then for clinical variables.
Results: Patients with lower SES were more frequently African-American and smokers, and were less likely to receive smoking cessation counseling 
than those with higher SES. Compared to the highest SES (Quintile 5), PAD patients in lower SES quintiles were less likely to receive cardioprotective 
medications (Table). These differences were markedly attenuated after controlling for practice site.
Conclusion: PAD patients with lower SES are less likely to receive antiplatelet and statin therapy. These differences, however, are largely explained 
by the clinical practice at which patients receive care, suggesting different patterns of care at these centers. Future efforts to reduce treatment 
disparities and improve outcomes in these vulnerable populations should target practices serving high proportions of patients with low SES. 
Unadjusted and Adjusted Rates of Medication Use Among Quintiles of Socioeconomic Status (Using the Highest Level of Socioeconomic Status 
[Quintile 5] as Reference)
Therapies
Unadjusted
(OR, 95% CI)
Adjustment for Practice Level Variation
(OR, 95% CI)
Adjustment for Clinical Characteristics*
(OR, 95% CI)
Statin Therapy (Reference Quintile 5)
Quintile 4 0.95 (0.94, 0.96) 0.98 (0.97, 1.00) 0.99 (0.97, 1.00)
Quintile 3 0.96 (0.95, 0.97) 0.98 (0.97, 1.00) 0.99 (0.98, 1.00)
Quintile 2 0.90 (0.89, 0.91) 0.97 (0.95, 1.00) 0.98 (0.96, 1.00)
Quintile 1 0.83 (0.82, 0.85) 0.96 (0.95, 0.98) 0.98 (0.96, 0.99)
Any antiplatelet (Reference Quintile 5)
Quintile 4 0.99 (0.98, 1.00) 1.00 (0.99, 1.01) 1.01 (1.00, 1.02)
Quintile 3 1.00 (0.99, 1.01) 0.99 (0.98, 1.01) 1.00 (0.99, 1.01)
Quintile 2 0.98 (0.97, 0.99) 1.00 (0.99, 1.01) 1.01 (0.99, 1.02)
Quintile 1 0.93 (0.92, 0.94) 0.98 (0.97, 1.00) 0.99 (0.98, 1.01)
*Adjusted for age, gender, history of MI, history of revascularization
